312 related articles for article (PubMed ID: 35399527)
1. Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance.
Deng J; Zhou M; Liao T; Kuang W; Xia H; Yin Z; Tan Q; Li Y; Song S; Zhou E; Jin Y
Front Cell Dev Biol; 2022; 10():818453. PubMed ID: 35399527
[TBL] [Abstract][Full Text] [Related]
2. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.
Jiang Z; Lim SO; Yan M; Hsu JL; Yao J; Wei Y; Chang SS; Yamaguchi H; Lee HH; Ke B; Hsu JM; Chan LC; Hortobagyi GN; Yang L; Lin C; Yu D; Hung MC
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33855973
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R; Xu J; Zhang B; Liu J; Liang C; Hua J; Meng Q; Yu X; Shi S
J Hematol Oncol; 2020 Aug; 13(1):110. PubMed ID: 32778143
[TBL] [Abstract][Full Text] [Related]
4. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.
Yu L; Huang K; Liao Y; Wang L; Sethi G; Ma Z
Cell Prolif; 2024 Apr; ():e13644. PubMed ID: 38594879
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy.
Gu X; Liu Y; Dai X; Yang YG; Zhang X
Front Immunol; 2023; 14():1137107. PubMed ID: 36926345
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
7. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.
Gao W; Wang X; Zhou Y; Wang X; Yu Y
Signal Transduct Target Ther; 2022 Jun; 7(1):196. PubMed ID: 35725836
[TBL] [Abstract][Full Text] [Related]
8. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
9. Non-apoptotic regulated cell death mediates reprogramming of the tumour immune microenvironment by macrophages.
Sun C; Zhan J; Li Y; Zhou C; Huang S; Zhu X; Huang K
J Cell Mol Med; 2024 Apr; 28(8):e18348. PubMed ID: 38652105
[TBL] [Abstract][Full Text] [Related]
10. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
[TBL] [Abstract][Full Text] [Related]
11. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
Xiong W; Zhao Y; Du H; Guo X
Front Oncol; 2021; 11():704336. PubMed ID: 34490104
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
Lecis D; Sangaletti S; Colombo MP; Chiodoni C
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060225
[TBL] [Abstract][Full Text] [Related]
13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
14. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.
Fan F; Liu P; Bao R; Chen J; Zhou M; Mo Z; Ma Y; Liu H; Zhou Y; Cai X; Qian C; Liu X
Cancer Res; 2021 Dec; 81(24):6233-6245. PubMed ID: 34711611
[TBL] [Abstract][Full Text] [Related]
15. A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma.
Cai Y; Liang X; Zhan Z; Zeng Y; Lin J; Xu A; Xue S; Xu W; Chai P; Mao Y; Song Z; Han L; Xiao J; Song Y; Zhang X
Front Cell Dev Biol; 2021; 9():812422. PubMed ID: 35174170
[No Abstract] [Full Text] [Related]
16. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.
Wang B; Han Y; Zhang Y; Zhao Q; Wang H; Wei J; Meng L; Xin Y; Jiang X
Cell Biosci; 2023 Jun; 13(1):120. PubMed ID: 37386520
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of ferroptosis in cancer: a matter of context?
Catanzaro E; Demuynck R; Naessens F; Galluzzi L; Krysko DV
Trends Cancer; 2024 May; 10(5):407-416. PubMed ID: 38368244
[TBL] [Abstract][Full Text] [Related]
18. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
19. Emerging roles of ferroptosis in the tumor immune landscape: from danger signals to anti-tumor immunity.
Shi L; Liu Y; Li M; Luo Z
FEBS J; 2022 Jul; 289(13):3655-3665. PubMed ID: 34042258
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity.
Efimova I; Catanzaro E; Van der Meeren L; Turubanova VD; Hammad H; Mishchenko TA; Vedunova MV; Fimognari C; Bachert C; Coppieters F; Lefever S; Skirtach AG; Krysko O; Krysko DV
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
